{"id":3955,"date":"2022-05-04T16:10:55","date_gmt":"2022-05-04T20:10:55","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/"},"modified":"2026-09-24T00:07:06","modified_gmt":"2026-09-24T04:07:06","slug":"assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/","title":{"rendered":"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 4 mai 2022, 18h00 CEST<\/strong> \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce la tenue de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 25 mai 2022 \u00e0 9h00 au si\u00e8ge social de la Soci\u00e9t\u00e9, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France (*).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>(*) Avertissement :<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En fonction des imp\u00e9ratifs sanitaires et\/ou l\u00e9gaux, les modalit\u00e9s d\u2019organisation de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale des actionnaires pourraient \u00e9voluer. Les actionnaires sont donc invit\u00e9s \u00e0 consulter r\u00e9guli\u00e8rement le site de la Soci\u00e9t\u00e9 (<span style=\"color: #33bdbc\">www.gensight-biologics.com<\/span>) qui pourrait \u00eatre mis \u00e0 jour pour pr\u00e9ciser, le cas \u00e9ch\u00e9ant, les modalit\u00e9s d\u00e9finitives de participation \u00e0 cette Assembl\u00e9e G\u00e9n\u00e9rale en fonction des imp\u00e9ratifs sanitaires et\/ou r\u00e9glementaires.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019avis pr\u00e9alable comportant l\u2019ordre du jour et les projets de r\u00e9solutions a \u00e9t\u00e9 publi\u00e9 au <em>BALO<\/em> du 20 avril 2022, et compl\u00e9t\u00e9 parun addendum \u00e0 l\u2019avis pr\u00e9alable publi\u00e9 au BALO du 4 mai 2022. L\u2019avis de convocation sera publi\u00e9 au <em>BALO<\/em> et dans un journal d\u2019annonces l\u00e9gales le 9 mai 2022.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e \u00e9nonc\u00e9s par l\u2019article R. 22-10-23 du Code de commerce sont mis en ligne sur le site Internet de la Soci\u00e9t\u00e9 (<span style=\"color: #33bdbc\"><a style=\"color: #33bdbc\" href=\"https:\/\/www.gensight-biologics.com\">www.gensight-biologics.com<\/a><\/span>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e seront \u00e9galement tenus \u00e0 la disposition des actionnaires \u00e0 compter de la convocation de l\u2019Assembl\u00e9e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Il est pr\u00e9cis\u00e9 que le texte int\u00e9gral des documents destin\u00e9s \u00e0 \u00eatre pr\u00e9sent\u00e9s \u00e0 l&rsquo;Assembl\u00e9e, conform\u00e9ment notamment aux articles L. 225-115 et R. 225-83 du Code de commerce, sont mis \u00e0 disposition au si\u00e8ge social.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Jusqu&rsquo;au cinqui\u00e8me jour inclusivement avant la r\u00e9union, tout actionnaire peut demander \u00e0 la Soci\u00e9t\u00e9 de lui adresser les documents et renseignements mentionn\u00e9s aux articles R. 225-81 et R. 225-83 du Code de commerce, de pr\u00e9f\u00e9rence par email \u00e0 l\u2019adresse suivante\u00a0: <a href=\"mailto:ir@gensight-biologics.com\"><span style=\"color: #33bdbc\">ir@gensight-biologics.com<\/span><\/a>. Les actionnaires au porteur doivent justifier de cette qualit\u00e9 par la transmission d&rsquo;une attestation d&rsquo;inscription en compte.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"color: #33bdbc\"><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il. D\u00e9velopp\u00e9 dans le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), le principal produit candidat de GenSight Biologics, LUMEVOQ<sup>\u00ae<\/sup> (GS010 ; lenadogene nolparvovec), est actuellement en cours d&rsquo;examen pour enregistrement en Europe, et en phase III pr\u00e9alablement au d\u00e9p\u00f4t de la demande d\u2019autorisation de mise sur le march\u00e9 aux Etats-Unis (<em>Biologics License Application<\/em> [BLA]).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 4 mai 2022, 18h00 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce la tenue de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 25 [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[76,81],"post-year":[],"class_list":["post-3955","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-type-corporate","news-type-regulatory"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 4 mai 2022, 18h00 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce la tenue de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 25 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-04T20:10:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:07:06+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/05\\\/04\\\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/05\\\/04\\\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e\",\"datePublished\":\"2022-05-04T20:10:55+00:00\",\"dateModified\":\"2026-09-24T04:07:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/05\\\/04\\\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\\\/\"},\"wordCount\":598,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/05\\\/04\\\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/05\\\/04\\\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\\\/\",\"name\":\"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-05-04T20:10:55+00:00\",\"dateModified\":\"2026-09-24T04:07:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/05\\\/04\\\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/05\\\/04\\\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/05\\\/04\\\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/","og_locale":"fr_FR","og_type":"article","og_title":"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e - GenSight Biologics","og_description":"Paris, France, le 4 mai 2022, 18h00 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce la tenue de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 25 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/","og_site_name":"GenSight Biologics","article_published_time":"2022-05-04T20:10:55+00:00","article_modified_time":"2026-09-24T04:07:06+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e","datePublished":"2022-05-04T20:10:55+00:00","dateModified":"2026-09-24T04:07:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/"},"wordCount":598,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/","name":"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2022-05-04T20:10:55+00:00","dateModified":"2026-09-24T04:07:06+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/05\/04\/assemblee-generale-mixte-du-25-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires-a-lassemblee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 25 mai 2022 Modalit\u00e9s de mise \u00e0 disposition des documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3955"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3955\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3955"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3955"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3955"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3955"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}